Syncona — 2019 Investments
2 investments dated 2019 · listed companies and verified rows first · show all
Anaveon develops engineered antibodies targeting immune system regulatory nodes to treat autoimmune diseases by selectively eliminating or reprogramming pathogenic immune cells.
BiotechBasel, CH
Thaminda(Chief Business Officer)inLaetitia Pouzol(Chief Scientific Officer)in
Co-investorsNovartis Venture FundPfizer Venture InvestmentsPontifax Venture CapitalForbion
Cambridge, US
ENEJ KUSCER, PH.D.(Executive Officer)PETER VAN VLASSELAER, PH.D.(Director)HENRIJETTE RICHTER, PH.D.(Director)BERNARDUS MACHIELSE(Director)LUCAS DE BREED(Director)DAVID DE GRAAF, PH.D.(Executive Officer, Director)
Co-investorsInkefMission BiocapitalCanaan PartnersSofinnova Partners
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.





